This is a retrospective observational cohort study, the primary objective is investigate the activity and efficacy of anti PD-1 antibodies in children, adolescents and young adult melanoma patients, with radically resected or metastatic disease
The aim of the study is to evaluate the activity and efficacy of anti PD-1 antibodies in adolescent, childhood and young adult with early and advanced melanomas through a multicenter transnational European retrospective analysis Clinical outcomes will be retrospectively retrieved beginning from the primary diagnosis of melanoma. Clinical outcomes will be retrospectively evaluated starting from the time of start of treatment for up to a the most recent follow-up. Data collected will include demographic information, disease history, baseline conditions, clinical outcomes of interest.
Study Type
OBSERVATIONAL
Enrollment
70
Aix-Marseille Universite
Marseille, France
Institut Curie
Paris, France
Ospedale universitario della Charité
Berlin, Germany
rate of objective response
efficay of anti PD-1 antibodies in adolescent, childhood and young through Tumor assessment revision adult with early and advanced melanomas
Time frame: 12 months
adverse event incidence
Number of AE occurred during treatment defined using CTCAE v5.0
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
German Cancer Research Center (Deutsches Krebsforschungszentrum (DKFZ)
Heidelberg, Germany
University Children's Hospital Tuebingen
Tübingen, Germany
Universita Degli Studi Di Firenze
Florence, Italy
Fondazione Irccs Istituto Nazionale Dei Tumori
Milan, Italy
Universita Cattolica Del Sacro Cuore
Roma, Italy
Princess Máxima Center for Pediatric Oncology (Prinses Máxima Centrum voor kinderoncologie)
Utrecht, Netherlands
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Warsaw, Poland
...and 3 more locations